Celsion Corporation (CLSN) Announces Appointment Of Harriet Shelare To Director, Communications

LAWRENCEVILLE, N.J., April 27, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the appointment of Harriet Shelare as Director, Communications effective immediately. Ms. Shelare is an independent counselor with more than 20 years' experience in healthcare public relations, including media relations, issues management and public education campaigns. She was formerly an Executive Vice President for Ruder Finn Public Relations, where she headed US and Global account teams for Novartis vaccines, and, earlier, as a Senior Vice President for Femara, the Novartis aromatase inhibitor approved for the treatment of early breast cancer. Previously, at MS&L Public Relations, she headed the agency's support of Pfizer's Celebrex in scientific data, regulatory activities, and medical meeting presentations and data publications. As a Managing Director for Hill & Knowlton's Healthcare Media Practice, she supported numerous FDA approvals, product launches and public education campaigns. She began in healthcare public relations as a media relations manager for Memorial Sloan-Kettering Comprehensive Cancer Center, after a career at CBS News and WCBS, where she was an executive producer.

Ms. Shelare may be contacted at [email protected] .

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer.  The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers.  Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas, TheraSilence and RAST .  For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission.  Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact

Jeffrey W. Church
Senior Vice President and CFO
609-482-2455
[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/celsion-corporation-announces-appointment-of-harriet-shelare-to-director-communications-300071595.html

SOURCE Celsion Corporation

Suggested Articles

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.

The trial has been paused since early September while FDA reviews the safety of the vaccine in light of a reported case of an inflammatory disorder.

Biogen is cutting its experimental multiple sclerosis drug opicinumab as well as an spinal muscular atrophy candidate amid a third-quarter clear-out.